436 related articles for article (PubMed ID: 34502204)
1. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
[TBL] [Abstract][Full Text] [Related]
2. Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Pawlak E; Frydecka I; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982802
[TBL] [Abstract][Full Text] [Related]
3. Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4
Alrasheed N; Lee L; Ghorani E; Henry JY; Conde L; Chin M; Galas-Filipowicz D; Furness AJS; Chavda SJ; Richards H; De-Silva D; Cohen OC; Patel D; Brooks A; Rodriguez-Justo M; Pule M; Herrero J; Quezada SA; Yong KL
Clin Cancer Res; 2020 Jul; 26(13):3443-3454. PubMed ID: 32220887
[TBL] [Abstract][Full Text] [Related]
4. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.
Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y
Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors for cancer treatment.
Park J; Kwon M; Shin EC
Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
[TBL] [Abstract][Full Text] [Related]
6. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
[TBL] [Abstract][Full Text] [Related]
7. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
Haematologica; 2017 Mar; 102(3):562-572. PubMed ID: 27927767
[TBL] [Abstract][Full Text] [Related]
8. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
Kwek SS; Lewis J; Zhang L; Weinberg V; Greaney SK; Harzstark AL; Lin AM; Ryan CJ; Small EJ; Fong L
Cancer Immunol Res; 2015 Sep; 3(9):1008-16. PubMed ID: 25968455
[TBL] [Abstract][Full Text] [Related]
9. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
10. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
Front Immunol; 2019; 10():1638. PubMed ID: 31379838
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway.
Chen D; Tang P; Liu L; Wang F; Xing H; Sun L; Jiang Z
Cell Cycle; 2018; 17(7):858-867. PubMed ID: 29493401
[TBL] [Abstract][Full Text] [Related]
12. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
13. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K
Front Immunol; 2021; 12():618610. PubMed ID: 33717112
[TBL] [Abstract][Full Text] [Related]
14. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
[TBL] [Abstract][Full Text] [Related]
15. MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection.
Zheng X; Dong L; Wang K; Zou H; Zhao S; Wang Y; Wang G
Ann Surg Oncol; 2019 Mar; 26(3):884-893. PubMed ID: 30565043
[TBL] [Abstract][Full Text] [Related]
16. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
17. Expression of immune checkpoints in T cells of esophageal cancer patients.
Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
[TBL] [Abstract][Full Text] [Related]
18. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
Taylor NA; Vick SC; Iglesia MD; Brickey WJ; Midkiff BR; McKinnon KP; Reisdorf S; Anders CK; Carey LA; Parker JS; Perou CM; Vincent BG; Serody JS
J Clin Invest; 2017 Sep; 127(9):3472-3483. PubMed ID: 28825599
[TBL] [Abstract][Full Text] [Related]
19. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
[TBL] [Abstract][Full Text] [Related]
20. PD-1 has a unique capacity to inhibit allergen-specific human CD4
Rosskopf S; Jahn-Schmid B; Schmetterer KG; Zlabinger GJ; Steinberger P
Sci Rep; 2018 Sep; 8(1):13543. PubMed ID: 30201974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
